ProShare Advisors
MRNA icon

ProShare Advisors’s Moderna MRNA Stock Holding History

ProShare Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.4M Buy
74,898
+4,277
+6% +$461K 0.02% 316
2026
Q2 		$4.95M Sell
70,621
-721
-1% -$37.3K 0.01% 561
2026
Q1 		$3.62M Sell
71,342
-14,122
-17% -$659K 0.01% 607
2025
Q4 		$2.52M Buy
85,464
+8,029
+10% +$218K ﹤0.01% 674
2025
Q3 		$2M Buy
77,435
+2,367
+3% +$66K ﹤0.01% 696
2025
Q2 		$2.07M Buy
75,068
+3,183
+4% +$83.8K ﹤0.01% 685
2025
Q1 		$2.04M Buy
71,885
+1,632
+2% +$57.9K ﹤0.01% 672
2024
Q4 		$2.92M Sell
70,253
-359,045
-84% -$17.2M 0.01% 619
2024
Q3 		$28.7M Buy
429,298
+27,750
+7% +$2.55M 0.07% 224
2024
Q2 		$47.7M Sell
401,548
-43,073
-10% -$5.45M 0.13% 142
2024
Q1 		$47.4M Buy
444,621
+78,017
+21% +$7.86M 0.13% 148
2023
Q4 		$36.5M Sell
366,604
-61,975
-14% -$5.21M 0.11% 173
2023
Q3 		$44.3M Buy
428,579
+53,937
+14% +$6.02M 0.14% 135
2023
Q2 		$45.5M Sell
374,642
-29,289
-7% -$3.91M 0.13% 132
2023
Q1 		$62M Buy
403,931
+37,368
+10% +$6.16M 0.19% 114
2022
Q4 		$65.8M Sell
366,563
-51,985
-12% -$8.5M 0.23% 102
2022
Q3 		$49.5M Sell
418,548
-83,002
-17% -$12.6M 0.19% 108
2022
Q2 		$71.6M Sell
501,550
-260,438
-34% -$37.2M 0.24% 107
2022
Q1 		$131M Sell
761,988
-28,621
-4% -$4.82M 0.28% 102
2021
Q4 		$201M Buy
790,609
+246,204
+45% +$72M 0.39% 50
2021
Q3 		$210M Buy
544,405
+87,676
+19% +$32.3M 0.59% 26
2021
Q2 		$107M Sell
456,729
-9,111
-2% -$1.63M 0.31% 102
2021
Q1 		$61M Buy
465,840
+70,703
+18% +$10.2M 0.19% 127
2020
Q4 		$41.3M Buy
395,137
+50,961
+15% +$5.16M 0.15% 141
2020
Q3 		$24.4M Buy
344,176
+277,285
+415% +$19.3M 0.11% 159
2020
Q2 		$4.3M Buy
66,891
+17,274
+35% +$946K 0.02% 422
2020
Q1 		$1.49M Sell
49,617
-27,384
-36% -$630K 0.01% 526
2019
Q4 		$1.51M Buy
+77,001
New +$1.37M 0.01% 681

Other funds holding MRNA

Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures
Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
Lingotto Investment Management
Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Leonteq Securities AG
Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

ProShare Advisors's MRNA Position: Q3 2026 in Review

ProShare Advisors increased its Moderna (MRNA) stake by 6.1% in Q3 2026, buying an estimated $461K and bringing the position to 74,898 shares worth $14.4M. The position accounts for 0.02% of the portfolio, ranked #316.

ProShare Advisors first reported a position in MRNA in Q4 2019 and has held it in 28 quarters since. The position peaked at $210M in Q3 2021. 330 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • ProShare Advisors held 74,898 shares of Moderna worth $14.4M as of Q3 2026.
  • ProShare Advisors bought 4,277 Moderna shares in Q3 2026, an estimated $461K.
  • Moderna made up 0.02% of ProShare Advisors's portfolio in Q3 2026, its #316 holding.
  • ProShare Advisors first reported a position in Moderna in Q4 2019 and has held it in 28 quarters since.
  • ProShare Advisors's Moderna position peaked at $210M in Q3 2021.
  • 330 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.